Acumen Pharmaceuticals to Present at Stifel 2026 Virtual CNS Forum
Event summary
- Acumen Pharmaceuticals will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026, at 11:00 a.m. ET.
- The company is developing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease.
- Acumen is conducting a Phase 2 clinical trial (ALTITUDE-AD) for early symptomatic Alzheimer’s patients.
- The company is also exploring a subcutaneous formulation of sabirnetug using Halozyme’s ENHANZE® technology.
The big picture
Acumen Pharmaceuticals’ participation in the Stifel 2026 Virtual CNS Forum underscores its focus on advancing sabirnetug through clinical trials. The company’s strategic partnerships with Halozyme and JCR Pharmaceuticals highlight its efforts to enhance drug delivery and brain penetration, critical factors in the Alzheimer’s disease market. The outcome of the Phase 2 trial will be a key determinant of its future trajectory in a sector dominated by high-stakes R&D and regulatory hurdles.
What we're watching
- Clinical Progress
- How the Phase 2 ALTITUDE-AD trial results will impact Acumen’s valuation and investor confidence.
- Strategic Partnerships
- Whether collaborations with Halozyme and JCR Pharmaceuticals will accelerate sabirnetug’s development and market entry.
- Market Dynamics
- The pace at which Acumen can differentiate itself in the competitive Alzheimer’s disease therapeutic landscape.